Drug Profile
GAL 021
Alternative Names: GAL021Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Galleon Pharmaceuticals
- Class Nitroso compounds; Small molecules
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory insufficiency
Most Recent Events
- 23 Feb 2023 Discontinued - Phase-I for Respiratory insufficiency in USA (IV)
- 23 Feb 2023 Discontinued - Preclinical for Respiratory insufficiency in USA (PO)
- 28 May 2018 No recent reports of development identified for phase-I development in Respiratory-insufficiency in USA (IV)